RE:RE:RE:NBF report is outThat's my plan. Their Board is overloaded with the Montreal Business community stalworts. That is not what a company Board hoping to be a global pharma firm shoudl look like. That's one where they're all looking to cover each others backs with groupthink, get help into the next country club or elite kids school or have solid cocktail banter for the next party. Since they all only know the same 50 business people who all live in Westmount, there's no global-reaching network for Paul to tap in to; hence, the OO. They desperately needed someone who had solid contacts in to the global world of investment banking, not just the tiny Bay St. world, and at a minimum pharma or biotech. They've added a few in global pharma, but just as many that are locally focused, wealthy empty suits.
They need to jettison this local business, board-(w)hore mentality and get challenging people in there that have VC and financial success investing in biotechs and know what it takes. I daresay Mr. Molson couldn't at this point tell you the 6 key advantages of the PDC over the ADC. But he can pour a mean pint with no head on it.
Lee430 wrote: Wino,
If I recall correctly these are the two I did not vote for last year and when looking at the vote tabulation I was not alone in that effort....Hopefully some of the highly experienced members of this board will help pull us together as one LARGE voice for some common sense change. ”Common sense is not so common”
Wino115 wrote: If NBF didn't at least review oncology and how the trial just started and what the significant data story told, then it's criminal and clearly a blow-off of the mangement and name. If I recall, his target is well below the current price so if he didn't change it, he is on a sell and believes you will lose money over the next 12-18 months.
This explains two things -- why we keep seeing NBF participating heaviliy in trading as their clients jettison it since their analyst thinks it's wildly overvalued and likely telling clients to sell if they ask; and, two, Leno is an incompetent nincomepoop, and not just because he doesnt' agree with me, but because he doesn't even know the key issues that will drive the share price. If Paul had any sense, he'd completely shut off any relationship with these Knights of Nee idiots.
We also now have out list of which Board members to boot off:
The two with NBF ties -- Paul Pommier and Gary Littlejohn. If either is up for election, time to send our message! They will not be getting my votes.
SPCEO1 wrote: I am not sure you could really call it a report, however. Not much effort was expended in producing it - I am guessing he may have dedicated 30 minutes to this. It is more evidence of bad blood between the company and Bay Street. The analyst, however, did not reduce his target price, however. Which I was surprised about given the revenue shortfall.
Like all of us, the NBF analyst is perturbed by the jumpy quarterly sales trends. I think that can partly be blamed on attempts to manage quarterly sales, as noted earlier, by stuffing the distribution channel in one quarter and hoping sales pick up enough in the following quarter to cover your tracks. But that pick-up never happens and sales look lumpier than they probably actually are on the ground.